CD4 and neoplasm: Platelets from NSCLC patients were found to express PD-L1, and platelet PD-L1 possesses the ability to inhibit CD4 and CD8 T cells, confirming their important roles in tumor immune evasion and overcoming the limitations of histological quantification of heterogeneous intratumoral PD-L1 expression [243].